Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Recommends Genetic Testing For Plavix, Opens Window For Effient

Executive Summary

FDA's latest revision to Plavix labeling on the issue of poor response in slow metabolizers has heightened the concerns to the highest level - that of a "black box" warning - and recommends use of testing to identify genetic differences in patients' metabolizing function. But FDA officials note that the testing won't be practical in all treatment settings - which leaves another opening for Lilly/Daiichi Sankyo to push use of their competitor Effient

You may also be interested in...



For Effient And Brilinta, A Formidable Competitor Grows More So

Plavix was a tough competitor before it went generic; now that cheap versions of the clot-buster are available, the market will prove even more challenging for the remaining branded antiplatelet drugs.

Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?

The role of newer antiplatelet agents such as Effient (prasugrel) is partly dependent on the prospects for optimizing Plavix (clopidogrel), but the feasibility of using diagnostic tests to make sure the soon-to-be generic drug is working properly remains a matter of debate in cardiology.

Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?

The role of newer antiplatelet agents such as Effient (prasugrel) is partly dependent on the prospects for optimizing Plavix (clopidogrel), but the feasibility of using diagnostic tests to make sure the soon-to-be generic drug is working properly remains a matter of debate in cardiology.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel